Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi (IST:GENIL)

Turkey flag Turkey · Delayed Price · Currency is TRY
10.34
-0.02 (-0.19%)
At close: Apr 17, 2026
Market Cap46.53B +6.5%
Revenue (ttm)19.18B -0.6%
Net Income814.44M +318.5%
EPS0.15 +251.2%
Shares Out4.50B
PE Ratio68.09
Forward PEn/a
Dividend0.05 (0.47%)
Ex-Dividend DateNov 12, 2025
Volume51,363,310
Average Volume45,340,563
Open10.40
Previous Close10.36
Day's Range10.10 - 10.42
52-Week Range7.12 - 14.93
Beta0.14
RSI58.19
Earnings DateMay 8, 2026

About IST:GENIL

Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi, a pharmaceutical company, manufactures and supplies products to treat rare diseases and disorders worldwide. The company offers its products in various areas, such as neurology, endocrinology, nephrology, oncology, hematology, and pediatric. Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi has collaboration with Sulfateq BV for the development of molecule SUL-238 as a treatment for Alzheimer's disease and other neurodegenerative diseases. In addition, it manufactures, tra... [Read more]

Sector Healthcare
Founded 1997
Employees 682
Stock Exchange Istanbul Stock Exchange
Ticker Symbol GENIL
Full Company Profile

Financial Performance

In 2025, IST:GENIL's revenue was 19.18 billion, a decrease of -0.59% compared to the previous year's 19.29 billion. Earnings were 814.44 million, an increase of 318.50%.

Financial Statements